Clarity Pharmaceuticals Ltd has released a press release.
US FDA Study May Proceed letter for Cu-64 SAR-bisPSMA
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Clarity receives $3.26 million R&D tax incentive refund
- SARTATE Neuroblastoma trial advances to cohort 2
- Managing Directors Presentation to Annual General Meeting
- Quarterly Activity Report
- Dosimetry Recruitment of theranostic prostate trial complete
Later from Clarity Pharmaceuticals
- First patient treated in cohort 2 neuroblastoma trial
- Update on China Grand Pharmaceutical and Healthcare Holdings
- Half Year Accounts
- Clarity Half Yearly Report
- First patient treated in the prostate cancer imaging trial
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals